Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pine Trees
Cambridge, Massachusetts, United Statesearthobservatory.nasa.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PineTree Therapeutics is a preclinical-stage biotechnology company developing next-generation bispecific and multi-specific antibodies for oncology. Its lead asset—a pan-EGFR degrader—has shown promising preclinical anti-tumor activity against drug-resistant and tyrosine kinase inhibitor–resistant tumors. The company’s proprietary AbReptor™ platform enables targeted degradation of membrane-bound/extracellular proteins. In July 2024 it signed a major licensing deal with AstraZeneca for its EGFR degrader program worth $45M upfront plus up to $500M in milestones and royalties if commercialized[5][6].
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Bispecific monoclonal antibodyMonoclonal antibody (multi-specific)Antibody-drug conjugate (ADC) [platform application]Protein degrader (targeted protein degradation)Biologic [general]
- Industry
- Biotech
02
Partnerships
AstraZeneca – exclusive option/license agreement for global development/commercialization of pan-EGFR degrader ($45M upfront + up to $500M milestones + royalties)[5][6]
Beyond the preview
Go deeper on Pine Trees.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pine Trees.